Find Clinical Trial

Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study. SHIFT


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationHeart failure
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

IVABRADINE,
S016257

Active Substance CodeS016257
Protocol CodeCL3-16257-063
EudraCT Code2006-000708-18
NCT CodeNCT02441218
ISRCTN CodeISRCTN70429960


Documents and links

Results summary READ MORE
First scientific publication READ MORE
Second scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility